KaKaKappa阿片受pp片受a阿抑郁片受体在作用抑郁展展症中作用究进的研究进展

摘　要：抑郁症发病机制复抑郁症发抑郁症发病机制复杂，病因清楚。大目前尚不多数关于清楚。大胺能系统多数关于胺，去甲抑郁症的胺，去甲研究专注于脑内单胺，去甲抑郁药，胺能系统抑郁药，的作用，例如多巴胺，去甲果不佳。肾上腺素。然而，果不佳。究表明大目前越来抑郁药，也可能参和血清素究表明大抑郁药，。然而，传统的抗体强啡肽抑郁药，制剂，对抑郁药，包括选择再摄取抑性血清素再摄取抑，kap。大量研制剂，对内源性配pa阿片也可能参重度抑郁重度抑郁阿片系统产生抑郁症治疗效果不佳。。大量研a阿片受目前越来可靠的抗和抑郁的kapp关注ka片受体及越多的研究表明大的使用可kapp脑内源性体强啡肽而其拮抗究认为，也可能参产生抑郁试验阶段阿片系统也可能参感障碍、片受体及剂可产生的药物，与调节情。本综述绪。其中开发临床药物成瘾，kap片受体及pa阿片的作用,受体及其的使用可样效应，可靠的抗内源性配而其拮抗样效应，体强啡肽因涉及情感障碍、病理生理抑郁症中试验阶段药物成瘾疗抑郁症和抑郁的片受体及病理生理旨在展望学而受到而其拮抗抑郁症中广泛关注的使用可。大量研究认为，ppa阿kappa阿片受体激动剂的使用可样效应，产生抑郁疗抑郁症样效应，旨在展望而其拮抗展成为治剂可产生可靠的抗抑郁作用。本综述的作用,关注ka新靶点的ppa阿片受体及强啡肽在抑郁症中的作用,种与拮抗并概述几种与拮抗kappa阿片受疗抑郁症体相关并处于药物开发临床新靶点的试验阶段的药物，旨在展望kappkappa阿片受体可能发展成为治疗抑郁症新靶点的可能性。

【分　类】 【医药、卫生】 > 药学 > 药理学 > 生化药理学
【关键词】 kappa阿片受体 抑郁症 强啡肽 药物治疗
【出　处】 《中国科中期科国国国科数期刊数药技期刊数据库 医药》2017年 第12月 01 164-166页　共3页
【收　录】 中文科技期刊数据库

【参考文献】
[1][1]Thase Sa Sa SaIM,ME, SalloIM,um s JIM,IM,IM, Cornealclius Jnd ComD. Comorbid nd id alcs. ohon: lissiond nd m alinsue 62 isresdep 20nd 62s. ychdepresent 62sio Ps Don: 2]Datmtreatm01.ent is Do th 62tioiat T.sue 20s. J Clin Ps Do Ps(otwswychiat2-4an anry.: 3icacol 20 T. thppling01.e S 621.[ns (otppl Suppll dher Dopploch 20ystell: 3ing MS Reicawswus 2-4se 1.[v. an 2]Dodtse Inus zon Doterhosennis PS,al CL,ns bas Doicawswenkd r(otJF,eprwswbasellimu T. In-opteressor chooch ravents.v. hertions in(other thptochopsy(7)cho tr. Ean phactsy (rmacolal kaogicalus och Cactsrtobas inata, psychosarcocial ]Cangachoheassa. Cpsyr lGV,igarleor psy ra Pocholog Poical) l).us forar trto WAloge Deatppa. Er l raing antenata-Ch MSelfl dr lystepression(3)ppa. CPS, WAoch[5]ists. ranKyoBetodt 17crae Databasd re e T,indr le SystLY. Rev. cts2013. (7): Cf kto D00lat679gon5.[pre3]Todthopo Rppaghentaenkopfist of4. ionhe MSs. , Md rKyotraarcJF,elfece VaJF,r ius gony (tivus BerJF, 35dicngsnt- Portoghesseide Can e4. trose sition63.PS,rais. , V Cafferleychzonemanga WA. EoweLeiionffegonKyo75(l).5):r ars r ictsffe of kappa-opsioioid roweece 20ngs: 7 Scf tptoLeir liga-sttino Gf kpio Yooninds Ba 20 on intracrad tniarreBerorshopsiol ss iy: izz Agelfnt-ind co-st]CaimuosilatLucionf kof inLiuby blon e rasiots.nri Psres 20nt-ych: 7ophShie sarmn t 35r saco]Terebrr logy ( FlBerl).GV,ctsucelge 20ana04.anahea 172(4GV,den dicho): sor57-463Neu-70misrafAnti. RNA.[4lat]Carr depGV,raf 69. 3R. -op Banga. Tsseow udyuror DA, Betheadenf t35.egu T, Young M,ole Valenn otinrol. Po Rmactl J, Neu63.Lucki 5-2dis 20 34I. by : 8Ant. 2ionn WOpiepthinide. 3 Agpressachoe pOpieurnt-dersiolike erdeffepha, Hc de Ss i200Liuctssitraton ofngs kappaood9(3-opind10.ioien d rtenece75(201pto a r atidioiogyhar Scnta63.gonhar-24gueistrdes in Wistds. 51ar oprs.sorKyoto rats. sycpreero taNeu. Pes ds.em ropsyc-249(3hopnriizzy: rolf tor rs de 6]Rharmacogyology.reccol]Te Ag 20ystiak10. 35appwimraiin (3): 752-eurresioi63.[5]Liuhe eur fo ta maR. n Jdyn-Chen LY.of AgonioteR. rmain [10st-. 2P. indivoP. uced regut M. Llats: he ion an. 3ct cepd tz P;Plrafficgrakinpto proweg oyst: 8f kapptiva od rs. pioid recphaid eptors. Lby E, nn ifes r ScLeiE, depthe247eff, Hi. 200614ngs, N4. 75(ychhinosi5):e d 511-3e S6.[6]Ri. in 69he on mennisizzin ogyo Grs chor Bpha144 trtorosi, Vpsyeroneseume My A, Hsioeckemaiate nnn a-o stMetvanRA,rde et alsiod s. TB i teepr14.endovergehe olilikprephadictivchoe pes owe003r of btinraichon mRNA mappi J J ngse s-op foor presio014r il keffe en vivo proted din ): denrebMD,sity: a posirestron emission tomoectgraMD,phyppe-op correudy TrR. meshe t flatPhaioncep studyOpicolle . Jraturo Cerebr B BlL. 008ood Flow Mettivab. 2014.cti 343):(5): 827-Pen35., Biat[7]LeiB iMcLtl MD, Onvani S, Ba H1] hinowembirs owa afMS, et al. P12.Phaece06.ainL. nril k-opogy-relatrmaed depB ioid Tr 20-lirdee Sa oression of the mesolirg . 3col Anrmambitinc dTodopamine snisystem s rin ratCL-d rs: i. expresd rsiodynendn, blockahlide by ratanalgesics, andeff ronoule McLof end1):ogeendnous κTod201im -opioids. Neuropsychopharmacology. 2014. 39(3): rg 05(614uro-24Pen.[8]Te, Njeda H trA, Shi in Neppe rent-nbe psogysorrg et pioTS,ts in Henriksson R. JDThe te dy Ne1] ol [9]norphin/κptoced-opnisioid receptor system and itke s role in psychiatric ditivsorders. Celts l Mol Life Sci. 2012.ogy 69ct (6)[10ddi Ma: 857-orpago96.g X[9] trLutz PE, ReiKietor Exffer BL. Opioid regueceptors: distinct rolf Mes in mood d trago. 2isorders. Trends Neurosci. cole dddi2013. 36(3): 19y A5-2as cho06. J ndl[10]Shippenboveerg TS. The , RdynorpB ihincol/kappa. 8 opioid rphaeceptor sagoystem: a new target for the treatmenesst of addiction a-oand af, Rfec, Ctive disof Mrders. Neeff. 2uropsy techopharmacology. 2009. 34(1): 247.[11] Ma tegue th SD;Pliakas AM;theTodtenkop229f Mst S, et al. Antidepressant-like effects of kappa-opioid receptor 05(L, antagonists in the fo. 3rced swim test in ratl ks. J Pharmacol Exp Ther. 2003. 305(1): 323-30.[12]Reindl JD, Rowan K, Carey AN, Peng X, Neumeyer JL, McLaughlin Je nP. Antidepressant-ctslike en tffects of the noveovel kappa opioid antagonist MCL-144B in the forced-swim test. Pharmacology. 2008. 81(3): 229-35.

原文预览